Elevated pro-inflammatory CD4+CD28- lymphocytes and stroke recurrence and death

Neurology

Volumn 63, Issue 8, 2004, Pages 1446-1451

  Nadareishvili, Z G ^a   Li, H ^a   Wright, V ^a   Maric, D ^a   Warach, S ^a   Hallenbeck, J M ^a   Dambrosia, J ^a   Barker, J L ^a   Baird, A E ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; AGED; ARTICLE; DEATH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; STROKE; T LYMPHOCYTE SUBPOPULATION;

EID: 7044269130     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000142260.61443.7C     Document Type: Article

References (32)

1. Hallenbeck JM. Inflammatory reactions at the blood-endothelial interface in acute stroke. Adv Neurol 1996;71:281-300.
2. Curb JD, Abbott RD, Rodriguez BL, et al. C-Reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003;107:2016-2020.
3. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
4. van Exel E, Gussekloo J, de Craen AJ, et al. Inflammation and stroke: the Leiden 85-Plus Study. Stroke 2002;33:1135-1138.
5. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23:1367-1379.
6. Garcia JH, Kamijyo Y. Cerebral infarction. Evolution of histopathological changes after occlusion of a middle cerebral artery in primates. J Neuropathol Exp Neurol 1974;33:408-421.
7. Ember JA, del Zoppo GJ, Mori E, et al. Polymorphonuclear leukocyte behavior in a nonhuman primate focal ischemia model. J Cereb Blood Flow Metab 1994;14:1046-1054.
8. Okada Y, Copeland BR, Fitridge R, et al. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994;25:1847-1853.
9. Garlichs CD, Kozina S, Fateh-Moghadam S, et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003;34:1412-1418.
10. Chen W, Wahl SM. TGF-beta: the missing link in CD4(+)CD25(+) regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003;14:85-89.
11. Weyand CM, Gorozny JJ, Liuzzo G, et al. T-Cell immunity in acute coronary syndromes. Mayo Clin Proc 2001;76:1011-1020.
12. Edmead CE, Lamb JR, Hoyne GF. The T cell surface protein, CD28. Int J Biochem Cell Biol 1997;29:1053-1057.
13. Markovic-Plese S, Cortese I, Wandinger KP, et al. CD4+CD28-costimulation- independent T cells in multiple sclerosis. J Clin Invest 2001;108:1185-1194.
14. Nakajima T, Schulte S, Warrington KJ, et al. T-Cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105:570-575.
15. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-2139.
16. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Study. Neurology 1994;44:626-634.
17. Adams HP Jr, Bendixen BH, Rappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993;24:35-41.
18. Plebanski M. Preparation of lymphocytes and identification of lymphocyte subpopulations. In: Rowland-Jones SL, McMichael AJ, eds. Lymphocytes: a practical approach. 2nd ed. New York: Oxford University Press, 2000:2-26.
19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980:87-89.
20. Vallejo AN, Schirmer M, Weyand CM, et al. Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J Immunol 2000;165:6301-6307.
21. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.
22. Vallejo AN, Weyand CM, Goronzy JJ. Functional disruption of the CD28 gene transcriptional initiator in senescent T cells. J Biol Chem 2001;276:2565-2570.
23. Liuzzo G, Gorozny JJ, Yang H, et al. Monoclonal T cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;102:2883-2888.
24. Becker KJ. Targeting the central nervous system inflammatory response in ischemic stroke. Curr Opin Neurol 2001;14:349-353.
25. Alvord EC Jr, Hsu PC, Thron R. Leukocyte sensitivity to brain fractions in neurological diseases. Arch Neurol 1974;30:296-299.
26. Youngchaiyud U, Coates AS, Whittingham S, Mackay IR. Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents. Aust NZ J Med 1974;4:535-538.
27. Lovett-Racke AE, Trotter JL, Lauber J, et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998;101:725-730.
28. + cells with identical CDR3 sequences. Clin Immunol Immunopathol 1998;89:61-70.
29. Vernino S, Brown RD Jr, Sejvar JJ, et al. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke 2003;34:1828-1832.
30. Hartmann A, Rundek T, Mast H, et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology 2001;57:2000-2005.
31. Kernan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 2000;31:456-462.
32. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32:803-808.